143 related articles for article (PubMed ID: 542935)
1. Spectrophotometric assays of prothrombin in plasma of patients using oral anticoagulants.
Bertina RM; van der Marel-van Nieuwkoop W; Loeliger EA
Thromb Haemost; 1979 Dec; 42(4):1296-305. PubMed ID: 542935
[TBL] [Abstract][Full Text] [Related]
2. The inhibitor of prothrombin conversion in plasma of patients on oral anticoagulant treatment.
Bertina RM; Westhoek-Kuipers ME; Alderkamp GH
Thromb Haemost; 1981 Jun; 45(3):237-41. PubMed ID: 7281102
[TBL] [Abstract][Full Text] [Related]
3. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment.
D'Angelo A; Della Valle P; Crippa L; Fattorini A; Pattarini E; Viganò D'Angelo S
Haematologica; 2002 Oct; 87(10):1074-80. PubMed ID: 12368163
[TBL] [Abstract][Full Text] [Related]
4. Des-gamma-carboxyprothrombin (PIVKA II) and plasma vitamin K1 in newborns and their mothers.
von Kries R; Shearer MJ; Widdershoven J; Motohara K; Umbach G; Göbel U
Thromb Haemost; 1992 Oct; 68(4):383-7. PubMed ID: 1448768
[TBL] [Abstract][Full Text] [Related]
5. Levels of acarboxy prothrombin (PIVKA-II) and coagulation factors in warfarin-treated patients.
Umeki S; Umeki Y
Med Lab Sci; 1990 Apr; 47(2):103-7. PubMed ID: 2381266
[TBL] [Abstract][Full Text] [Related]
6. Prevention of subclinical vitamin K deficiency based on PIVKA-II levels: oral versus intramuscular route.
Bakhshi S; Deorari AK; Roy S; Paul VK; Singh M
Indian Pediatr; 1996 Dec; 33(12):1040-3. PubMed ID: 9141807
[No Abstract] [Full Text] [Related]
7. Interference of lupus anticoagulants in prothrombin time assays: implications for selection of adequate methods to optimize the management of thrombosis in the antiphospholipid-antibody syndrome.
Della Valle P; Crippa L; Garlando AM; Pattarini E; Safa O; Viganò D'Angelo S; D'Angelo A
Haematologica; 1999 Dec; 84(12):1065-74. PubMed ID: 10586206
[TBL] [Abstract][Full Text] [Related]
8. [Influence of the protein induced by vitamin K absence on thrombotest and hepaplastintest in the patients treated with oral anticoagulant].
Murakami S; Muratani H; Kikuchi T; Fujimoto S; Hayashi T; Inai S; Imaoka S
Rinsho Byori; 1983 Jan; 31(1):105-9. PubMed ID: 6865023
[No Abstract] [Full Text] [Related]
9. Effect of oral water soluble vitamin K on PIVKA-II levels in newborns.
Sharma RK; Marwaha N; Kumar P; Narang A
Indian Pediatr; 1995 Aug; 32(8):863-7. PubMed ID: 8635828
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of subclinical vitamin K deficiency in cholestatic liver disease.
Strople J; Lovell G; Heubi J
J Pediatr Gastroenterol Nutr; 2009 Jul; 49(1):78-84. PubMed ID: 19502999
[TBL] [Abstract][Full Text] [Related]
11. Biological properties of the thromboplastins and plasmas included in the ICTH/ICSH collaborative study on prothrombin time standardization.
Loeliger EA; van Halem-Visser LP
Thromb Haemost; 1979 Dec; 42(4):1115-27. PubMed ID: 542924
[No Abstract] [Full Text] [Related]
12. Evidence of vitamin K deficiency in cord blood.
Mahasandana C; Pung-amritt P; Yodthong S; Suvatte V
Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():116-20. PubMed ID: 7886551
[TBL] [Abstract][Full Text] [Related]
13. The "echis carinatus venom" prothrombin assay in coumarin treated patients. A comparison with one-stage and immunological assays.
Girolami A; Brunetti A; Patrassi G; Borsato N
Folia Haematol Int Mag Klin Morphol Blutforsch; 1976; 103(5):746-57. PubMed ID: 64416
[TBL] [Abstract][Full Text] [Related]
14. Prediction of vitamin K response using the Echis time and Echis-prothrombin time ratio.
Solano C; Cobcroft RG; Scott DC
Thromb Haemost; 1990 Nov; 64(3):353-7. PubMed ID: 2096486
[TBL] [Abstract][Full Text] [Related]
15. Acarboxy prothrombin (PIVKA-II) in cord plasma in the south of Thailand.
Laosombat V; Kenpitak K; Wongchanchailert M; Wiriyasateinkul A
J Med Assoc Thai; 1993 May; 76(5):278-84. PubMed ID: 8006559
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of plasma PIVKA-II as a new marker for hepatocellular carcinoma].
Tada H; Kagawa K; Hikita H; Takeuchi T; Ohta Y; Fukui S; Shintani H; Deguchi T; Okanoue T; Takino T
Gan No Rinsho; 1989 Apr; 35(5):564-70. PubMed ID: 2469809
[TBL] [Abstract][Full Text] [Related]
17. [Prothrombin and acarboxyprothrombin activity in neonates after oral and intramuscular administration of vitamin K].
Goldschmidt B; Verbényi M; Kovács I; Ilin E; Varga K; Német T
Orv Hetil; 1990 Mar; 131(11):577-82. PubMed ID: 2314877
[TBL] [Abstract][Full Text] [Related]
18. [Clinical usefulness of plasma PIVKA-II assay and its limitations in patients with hepatocellular carcinoma].
Fujiyama S; Morishita T; Shibata J; Sato T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1129-38. PubMed ID: 2471453
[TBL] [Abstract][Full Text] [Related]
19. Clinical application of a new monoclonal antibody (19B7) against PIVKA-II in the diagnosis of hepatocellular carcinoma and pancreatobiliary malignancies.
Nakao A; Taniguchi K; Inoue S; Takeda S; Harada A; Nonami T; Watanabe K; Takagi H
Am J Gastroenterol; 1997 Jun; 92(6):1031-4. PubMed ID: 9177525
[TBL] [Abstract][Full Text] [Related]
20. Effects of oral and intramuscular vitamin K prophylaxis on PIVKA-II assay parameters in breastfed infants in Turkey.
Uluşahin N; Arsan S; Ertogan F
Turk J Pediatr; 1996; 38(3):295-300. PubMed ID: 8827897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
